Thursday, March 24, 2016

Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress

… (Supinoxin), Shows Activity in Triple-Negative Breast Cancer,” Rexahn’s collaborators at the … preclinical models of triple negative breast cancer (TNBC). “The nonclinical data for … form of breast cancer, which comprises approximately 20% of new breast cancer diagnoses,” said …

No comments:

Post a Comment